Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

New models emerge for commercializing university assets

Nature Biotechnology volume 29, pages 774–775 (2011)Cite this article

Subjects

A Corrigendum to this article was published on 09 January 2012

This article has been updated

Since the 2008 economic crisis, the mismatch between the volume of good research and the amount of capital available to commercialize it has become acute, according to Michael Cleare, executive director of the Center for Technology Transfer at the University of Pennsylvania in Philadelphia, one of BioPontis' eight academic partners. “There are a host of new ways people are trying to get around it, but given the economic situation, investors are more risk-averse than ever,” Cleare says.

For universities, finding new ways to finance the transformation of basic biology into assets pharma can feed into its pipelines has become a major preoccupation. Some universities are setting up their own seed and venture funds, such as London-based Imperial Innovations in the UK, others are collaborating directly with pharma and biotech companies (Nat. Biotechnol. 29, 555–556, 2011).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 09 January 2012

    In the version of this article initially published, in Box 1, the CEO at VPD is David Collier, not Michael Collier. On p. 775, second column, the University of Pennsylvania has 400 invention disclosures a year, and not, as stated, Penn State. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. London

    Nuala Moran

Authors
  1. Nuala Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moran, N. New models emerge for commercializing university assets. Nat Biotechnol 29, 774–775 (2011). https://doi.org/10.1038/nbt0911-774

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0911-774

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research